argenx SE launched a tender offer for Forte Biosciences, Inc. this morning, acquiring a clinical-stage atopic dermatitis program at what amounts to a $130 million enterprise value based on Forte's pre-announcement trading range. The deal pulls a struggling biotech into the argenx portfolio while argenx itself carries $2.8 billion in cash from its VYVGART franchise and maintains a $13 billion market capitalization on dual Amsterdam-Nasdaq listings.

Forte's lead asset, FB-401, is a lymphocyte function-associated antigen 1 (LFA-1) antagonist that completed a Phase 2b trial in moderate-to-severe atopic dermatitis with mixed topline results reported in mid-2023. The trial missed its primary endpoint on investigator-assessed severity but showed secondary signal on patient-reported itch scores, leaving the program in regulatory limbo. Forte's equity traded down 68% from its 2021 IPO price before this tender materialized, compressing valuation to roughly 1.2x trailing cash balances and eliminating the capital cushion needed for a Phase 3 solo effort.

The acquisition gives argenx a second dermatology shot on goal beyond its efgartigimod FcRn platform, which is approved as VYVGART for generalized myasthenia gravis and under regulatory review for chronic inflammatory demyelinating polyneuropathy. FB-401's mechanism—blocking T-cell adhesion to inflamed skin—sits orthogonal to argenx's core FcRn antagonism, broadening the company's immunology toolkit without overlapping its existing commercial infrastructure. argenx has $11.2 billion in trailing twelve-month VYVGART sales momentum and $487 million in operating cash generation, providing capital depth to rehabilitate Forte's clinical strategy without balance-sheet stress.

The tender structure suggests argenx sees salvage value in the LFA-1 dataset and wants optionality on a repositioned Phase 3 design, likely targeting a narrower atopic dermatitis phenotype or combination trial with an IL-4/IL-13 inhibitor. Forte's burn rate ran at $42 million annually before this offer, a manageable addition to argenx's $680 million R&D budget. The deal also removes a small-cap volatility name from public markets, consolidating dermatology innovation into a house with regulatory execution history and payer access in the autoimmune corridor.

Operators should track whether argenx files an IND amendment for FB-401 within 90 days of tender close, signaling intent to redesign the Phase 3 protocol. Watch for disclosures on combination-trial partnerships with dupilumab or tralokinumab manufacturers, which would validate the LFA-1 mechanism as adjunctive rather than standalone. The VYVGART label expansion decision in CIDP, expected Q2 2025, will clarify argenx's cash deployment capacity for follow-on acquisitions in the $200-400 million range.

The tender closes in 20 business days unless extended. argenx did not disclose premium to pre-announcement Forte pricing, but the enterprise value implies roughly 15-18% above the 30-day VWAP before tender rumors surfaced in late December.